Among these targeted therapeutic agents, TKI based on the EGFR mutations have been widely used in the clinic, and the ability to provide information on the EGFR mutations in clinical tumor tissues with the goal of guiding targeted therapy in a timely manner has become an important goal of lung cancer molecular detection [17–20]. Here, EGFR is linked to neoplasm.